Close

More on 688180

- Summary
- Chart
- Profile
- Historical

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Friends, Peers and Foes (?): 688180.SS, CHRS, 2M7C, 1PC LGNRF (more...)

Apr 24, 2024 10:11 PM Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
Apr 7, 2024 08:46 AM Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
Mar 29, 2024 12:24 AM Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates
Feb 1, 2024 10:40 PM Junshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences Authority
Jan 17, 2024 11:05 PM Junshi Biosciences Announces JAMA Publication of Results from NEOTORCH, a Randomized Phase 3 Trial of Perioperative Toripalimab plus Chemotherapy for Patients with Resectable Non-Small Cell Lung Cance
Jan 9, 2024 10:15 PM Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medi
Dec 1, 2023 10:39 PM Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia’s TGA
Nov 22, 2023 08:08 PM Junshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19
Oct 27, 2023 03:10 PM Coherus BioSciences (CHRS) and Junshi Biosciences Announce FDA Approval of LOQTORZI (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
Oct 27, 2023 03:07 PM Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
View All Articles

Entities mentioned with 688180

View All Entities